WuXi Biologics (Cayman)MEX:2269N 99 Operating Margin % is 34.44% as of Dec. 2025, which is 25% above its 10-year median of 27.61. GuruFocus rates MEX:2269N with a GF Score™ of 99/100 and a GF Value™ of MXN72.14. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 93.96% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
WuXi Biologics (Cayman) Operating Margin % Related Terms
WuXi Biologics (Cayman) Operating Margin % Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:2269N vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Operating Margin % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
WuXi Biologics (Cayman)'s Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (MEX:2269N) has a Operating Margin % of 34.44% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on WuXi Biologics (Cayman) and its competitors. This is 25% above median its historical median of 27.61. Over the past decade, WuXi Biologics (Cayman)'s Operating Margin % has ranged from 22.97 to 33.67. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #57 out of 944 companies in the Biotechnology industry, placing it in the top 6%.
Is WuXi Biologics (Cayman)'s Operating Margin % too high?
WuXi Biologics (Cayman)'s current Operating Margin % of 34.44% is 25% above median its 10-year median of 27.61. Over the past 10 years, this metric has ranged from a low of 22.97 to a high of 33.67. Based on the distribution chart, WuXi Biologics (Cayman) ranks #57 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #57 out of 944 companies for Operating Margin %. This places WuXi Biologics (Cayman) in the top 6% of its industry — outperforming the majority of peers. Historically, WuXi Biologics (Cayman)'s own Operating Margin % has ranged from 22.97 to 33.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Operating Margin % is 34.44%, which is 25% above median its own 10-year median of 27.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Operating Margin % of 34.44%. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Operating Margin % is 34.44%, which is 25% above median its 10-year median of 27.61. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Operating Margin % is 34.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Operating Margin %: 34.44% (25% above median its 10-year median of 27.61)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
